Pharma Research Library | Pharma Info Index Research | Innovation | Opportunities |
Sreemantula Divya*, Tummala Vaishnavi1, Tagore Jaya Sree1, Tharigoppula Harini1, P. Naveen Kumar1, Saritha Jyostna Tangeda1 , Venu Talla1
Sarojini Naidu Vanita Pharmacy Maha Vidyalaya, Tarnaka, Hyderabad, India.
A B S T R A C T
Cocktail is a composition of 2 antibodies Casirivimab and Imdevimab that is mostly given in the omicron variant of covid-19. The objectives of the study includes the post therapeutic effects, complications associated with administration if cocktail monoclonal antibodies. The methodology of the study is a prospective observational study was conducted for a period of 3 months. Ethical Committee clearance was obtained from Institutional Ethical Committee of Medicover Hospitals, Madhapur, Hyderabad. Data was collected from patient’s case sheets and electronic medical record, who were admitted in various wards of hospital for cocktail treatment for 3 months ( January 2022 to March 2022.), who fitted the inclusion criteria and the data was analyzed to know the cause of the covid-19 associated with different comorbid conditions, the management by using casirivimab and imdevimab antibodies. The study was resulted as From 42 enrolled patients gender, age, hospital stay days, comorbid type, No. of comorbid are classified and patients with end-stage diseases have undergone death. With no are less comorbid conditions have discharged earlier. Patients with high comorbid conditions had good protection. The hematological test like Hb, TLC, Platelets, IL-6, CRP, D-dimer were elevated and were normalized on discharge. The oxygen saturation levels have increased after treatment. Also the respiratory rate decreased from hyperventilation. Six deaths were recorded in 3 months they are with end-stage diseases of different organ system. The study are concluded as a revealed that Cocktail monoclonalantibodypreparation which contains Casirivimab and Imdevimab was proved to be safe, effective and had high margin to treat mild to moderate covid patients.
Keywords: Casirivimab, coronavirus 2, cocktail treatment and D-dimer.
